HL 5101

Drug Profile

HL 5101

Alternative Names: HL5101; NOV 1601

Latest Information Update: 24 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator CMG Pharmaceutical; Handok Inc
  • Class 2 ring heterocyclic compounds; Antineoplastics; Bridged-ring heterocyclic compounds; Heterocyclic compounds; Small molecules
  • Mechanism of Action Tropomyosin-related kinase antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 24 Jul 2017 Handok and CMG Pharmaceutical have patent protection for TRK inhibitors worldwide
  • 24 Jul 2017 Preclinical trials in Cancer in South Korea (unspecified route) (Handok pipeline, July 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top